Premium
Double‐Blind Comparison of Itraconazole with Griseofulvin in the Treatment of Tinea Corporis and Tinea Cruris
Author(s) -
Bourlond A.,
Lachapelle J. M.,
Aussems J.,
Boyden B.,
Campaert H.,
Conincx S.,
Decroix J.,
Geeraerts Ch.,
Ghekiere L.,
Porters J.,
Speelman G.,
Tennstedt D.,
Kint T.,
Vandaele R.,
Haute V.,
Lint L.,
Willocx D.
Publication year - 1989
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/j.1365-4362.1989.tb02491.x
Subject(s) - griseofulvin , itraconazole , tinea capitis , medicine , dermatology , cure rate , surgery , antifungal
ABSTRACT Seventy‐eight patients with tinea corporis or tinea cruris participated in a double‐blind study with either 100 mg itraconazole or 500 mg ultramicromized griseofulvin for 15 consicutive days. Clinical outcome was significantly in favor of itraconazole at completion of treatment (72% responce rate vs . 51%) and at the follow‐up visit(91% response vs . 64%). The most important difference berween both treatment was the mycologic outcome, for which itraconazole showed a cure rate oc 87% compared to 57% for griseofulvin 2 weeks after comparison of therapy. It is suggested that 100 mg of itraconazole orally daily is significantly more effective than 500 mg of griseofulvin once daily for 15 days in the treatment of glabrous skin infections. Both drugs were well tolerated.